Study Title: A Phase II Trial To Assess the Safety of Immunosuppression Withdrawal In Liver Transplant Recipients. (IRB#006-248)

Short Title: AWISH

Study Description: People who receive a liver transplant need to take medicine to prevent their body from rejecting their new liver.  Most patients take anti-rejection medicine for the rest of their lives.  All anti-rejection medicines – such as tacrolimus, cyclosporine, or mycophenolate - have side effects.  Because of these side effects, it may be helpful if an anti-rejection medication could be taken for a short period of time, then decreased, and eventually stopped, without a person losing (rejecting) the transplanted liver.  If the body accepts the transplanted liver without the need for anti-rejection medications, this is called tolerance.  This study is being done to look at how safe it is to slowly withdraw your anti-rejection medicines.  It will see if this can be done without your body rejecting your liver.  It will examine how your liver works and how your body responds as your anti-rejection medication is withdrawn.

Some of the criteria for patients to qualify for the study include:

• Male or female 18 years of age or older
• Necessity for liver transplant
  

The following are some of the criteria which will exclude patients from the study:

• Previous transplant
• Multi-organ or split liver transplant
• Living-donor transplant

Location:
Baylor University Medical Center                                             
Roberts Building-4th Floor                             
Dallas, TX 75246

Lead Principal Investigator:  Goran Klintmalm, MD

For further information about this study, please contact: 214-820-6622 or sharonb@baylorhealth.edu or you can complete our online form and a research coordinator will get back to you.